Independent Antibodies: Western Blot: Dopamine beta-Hydroxylase Antibody [NBP1-31386] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membranes were blotted with Dopamine beta ...read more
69 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publications using NBP1-31386 in the following applications:
The production of neurotransmitters is controlled by environmental stimuli, which send signals through second messengers and protein kinase pathways. Regulation of gene expression of dopamine beta hydroxylase and tyrosine hydroxylase, two of the catecholamine biosynthetic enzymes, by cyclic AMP, diacyl glycerol, and Ca2+ leads to increased neurotransmitter biosynthesis. Dopamine beta-hydroxylase catalyzes the conversion of dopamine to noradrenaline and is expressed selectively in noradrenergic and adrenergic neurons in the nervous system. The disruption of the DBH gene is thought to cause changes in development and behavior in certain models. Both DBH and the multiple regulatory pathways of DBH are of increasing research in many neurological diseases.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Dopamine beta-Hydroxylase Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.